ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have received a consensus rating of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $103.4286.

A number of research analysts have recently issued reports on the company. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Guggenheim boosted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a report on Friday, January 16th. Barclays started coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Finally, Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th.

ANI Pharmaceuticals Trading Down 0.2%

NASDAQ ANIP opened at $81.85 on Friday. ANI Pharmaceuticals has a one year low of $54.10 and a one year high of $99.50. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of 50.21 and a beta of 0.51. The company’s 50-day simple moving average is $81.90 and its two-hundred day simple moving average is $84.94.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The company’s revenue was up 53.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Equities analysts forecast that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Renee P. Tannenbaum sold 1,800 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $81.15, for a total transaction of $146,070.00. Following the transaction, the director directly owned 25,157 shares of the company’s stock, valued at approximately $2,041,490.55. This represents a 6.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Meredith Cook sold 500 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total value of $42,165.00. Following the transaction, the vice president owned 74,374 shares in the company, valued at approximately $6,271,959.42. This trade represents a 0.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 28,101 shares of company stock valued at $2,453,063. 11.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently modified their holdings of ANIP. Vanguard Group Inc. boosted its stake in ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares in the last quarter. Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals by 17.2% in the second quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock worth $56,251,000 after buying an additional 126,500 shares during the last quarter. UBS Group AG lifted its stake in shares of ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in shares of ANI Pharmaceuticals during the third quarter valued at $32,992,000. Finally, Rubric Capital Management LP grew its holdings in shares of ANI Pharmaceuticals by 33.3% during the third quarter. Rubric Capital Management LP now owns 343,414 shares of the specialty pharmaceutical company’s stock valued at $31,457,000 after buying an additional 85,745 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.